Author: PharmaSignal News Desk

Trump Kennedy vaccine policy changes could alter the U.S. childhood vaccine schedule, impacting development costs and availability.

Clinical trials access remains limited as only 24% of drugs tested in 89 countries are available post-approval.

Johnson & Johnson acquires Halda Therapeutics for $3.05 billion, marking a significant move in the PROTACs technology space.

Johnson & Johnson acquires Halda Therapeutics for $3.05 billion, enhancing its cancer treatment pipeline.

Agios Pyrukynd results show mixed outcomes in a crucial sickle cell study, affecting the drug’s commercial outlook.

Novo Nordisk Wegovy Pricing launches at $349 per month, months ahead of schedule, impacting the obesity drug market.

Scott Gottlieb joins UnitedHealth’s board, enhancing regulatory ties.

Sanofi AI ROI is about measurable improvements, not flashy demos, says CEO Paul Hudson.

Alkermes Avadel bid increases as the company aims to strengthen its position in the US market.

US CDC overdose warning highlights the risk of counterfeit medicines online, with fentanyl causing over 100,000 drug overdoses annually.